drugset / Trial / NCT00230594

Desmopressin Response in the Young

NCT00230594

Phase 3 Completed 132 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether desmopressin administered as a melt tablet is effective in reducing the number of wet nights in children and adolescents who suffer from bedwetting.

Timeline

Start
2004-07
Primary completion
2006-01
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Desmopressin Peptide 120 ug Oral
Comparator Desmopressin Peptide 240 ug Oral
Comparator Desmopressin Peptide 360 ug Oral